Feed NBIX
NB

Neurocrine Biosciences NBIX · NASDAQ

$135.71 -0.91% (-$1.24)

Market cap
$13.9B
Enterprise value
$14.0B
P/E
19.7x
Forward P/E
20.6x
PEG
0.7x
P/S
4.1x
P/FCF
16.0x
EV/EBITDA
15.2x
ROIC
13.2%
Gross margin
98.0%
Net margin
20.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
0.1x
Beta
0.40
Free float
98.7%

About the company

Neurocrine Biosciences, Inc. is an American biotechnology company headquartered in San Francisco, California. The company focuses on the development of drugs for the treatment of neurological and endocrine disorders. Their main products include medications for the treatment of sleep disorders, movement disorders, and endocrine disorders such as diabetes. Neurocrine Biosciences specializes in research and development of new drug formulations targeting specific biological targets related to neurological and endocrine diseases. The company is known for its innovative drugs and technologies that help patients with these serious conditions. Shares of Neurocrine Biosciences, Inc. are publicly traded on the NASDAQ stock exchange.

Sector

Healthcare

Industry

Biotechnology

CEO

Kyle W. Gano

Employees

2,500

Headquarters

San Diego

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.